 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CAPTOPRIL increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CAPTOPRIL increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CAPTOPRIL increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CAPTOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: warnings: [0m[1;31m)[0m[31m Fetal/Neonatal Morbidity and Mortality : ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have [0m
[31mbeen reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. The use of ACE inhibitors during the second and third trimesters of [0m
[31mpregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also [0m
[31mbeen reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic [0m
[31mlung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor [0m
[31mexposure. CAPTOPRIL: warnings: These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and [0m
[31mfetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of [0m
[31mcaptopril as soon as possible. Rarely [0m[1;31m([0m[31mprobably less often than once in every thousand pregnancies[0m[1;31m)[0m[31m, no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised[0m
[31mof the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment. If oligohydramnios is observed, captopril should be [0m
[31mdiscontinued unless it is considered life-saving for the mother. Contraction stress testing [0m[1;31m([0m[31mCST[0m[1;31m)[0m[31m, a non-stress test [0m[1;31m([0m[31mNST[0m[1;31m)[0m[31m, or biophysical profiling [0m[1;31m([0m[31mBPP[0m[1;31m)[0m[31m may be appropriate, depending upon the week [0m
[31mof pregnancy. CAPTOPRIL: warnings: Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Infants with histories[0m
[31mof in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and [0m
[31mrenal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. While captopril may be removed from the adult [0m
[31mcirculation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective [0m
[31mfor removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation. When captopril was given to rabbits at doses about [0m[1;31m0[0m[31m. CAPTOPRIL: [0m
[31mwarnings: [0m[1;31m8[0m[31m to [0m[1;31m70[0m[31m times [0m[1;31m([0m[31mon a mg/kg basis[0m[1;31m)[0m[31m the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of [0m
[31mpregnant rats and hamsters. On a mg/kg basis, the doses used were up to [0m[1;31m150[0m[31m times [0m[1;31m([0m[31min hamsters[0m[1;31m)[0m[31m and [0m[1;31m625[0m[31m times [0m[1;31m([0m[31min rats[0m[1;31m)[0m[31m the maximum recommended human dose. Hepatic Failure : Rarely, ACE Inhibitors [0m
[31mhave been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and [0m[1;31m([0m[31msometimes[0m[1;31m)[0m[31m death. The mechanism of this syndrome is not understood. [0m
[31mPatients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. Hydrochlorothiazide : [0m
[31mThiazides should be used with caution in severe renal disease. CAPTOPRIL: warnings: In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in [0m
[31mpatients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte [0m
[31mbalance may precipitate hepatic coma. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic [0m
[31mlupus erythematosus has been reported. In general, lithium should not be given with diuretics [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions: Hydrochlorothiazide [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: warnings: WARNINGS Captopril : Anaphylactoid and Possible Related Reactions : Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding captopril[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema [0m
[31m: Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If angioedema involves the [0m
[31mtongue, glottis or larynx, airway obstruction may occur and be fatal. Emergency therapy, including but not necessarily limited to, subcutaneous administration of a [0m[1;31m1:1000[0m[31m solution of epinephrine [0m
[31mshould be promptly instituted. CAPTOPRIL: warnings: Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of treatment; some [0m
[31mcases required medical therapy. [0m[1;31m([0m[31mSee PRECAUTIONS: Information for Patients and ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with [0m
[31mACE inhibitors. These patients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. [0m
[31mThe angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in[0m
[31mthe differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. CAPTOPRIL: warnings: Anaphylactoid Reactions During Desensitization : Two patients undergoing desensitizing [0m
[31mtreatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were [0m
[31mtemporarily withheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure : Anaphylactoid reactions have been reported in patients dialyzed with [0m
[31mhigh-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate [0m
[31mabsorption. Neutropenia/Agranulocytosis : Neutropenia [0m[1;31m([0m[31m< [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m with myeloid hypoplasia has resulted from use of captopril.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: information_for_patients: INFORMATION FOR PATIENTS Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema [0m[1;31m([0m[31me.g., swelling [0m
[31mof face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness[0m[1;31m)[0m[31m and to discontinue therapy. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal [0m
[31mAngioedema .[0m[1;31m)[0m[31m Patients should be told to report promptly any indication of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m, which may be a sign of neutropenia, or of progressive edema which might be related to [0m
[31mproteinuria and nephrotic syndrome. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. [0m
[31mOther causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. CAPTOPRIL: information_for_patients: [0m
[31mPatients should be advised not to use potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician. [0m[1;31m([0m[31mSee PRECAUTIONS: General and Drug[0m
[31mInteractions: Captopril ; ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Patients should be warned against interruption or discontinuation of medication unless instructed by the physician. Heart failure patients on [0m
[31mcaptopril therapy should be cautioned against rapid increases in physical activity. Patients should be informed that captopril and hydrochlorothiazide tablets should be taken one hour before meals [0m
[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: pharm_class_moa         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: boxed_warning: BOXED WARNING USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE Inhibitors can cause injury and even death to the developing fetus.[0m
[31mWhen pregnancy is detected, captopril and hydrochlorothiazide should be discontinued as soon as possible. See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality .         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: pregnancy: Pregnancy Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be [0m
[31mtold that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies [0m
[31mto their physicians as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m. CAPTOPRIL: adverse_reactions: Cough : Cough has been[0m
[31mreported in [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m% of patients treated with captopril in clinical trials [0m[1;31m([0m[31msee PRECAUTIONS: General: Captopril: Cough [0m[1;31m)[0m[31m. The following have been reported in about [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m percent of patients but [0m
[31mdid not appear at increased frequency compared to placebo or other treatments used in controlled trials: gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, [0m
[31maphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias. Other clinical adverse effects reported since the drug was marketed are [0m
[31mlisted below by body system. In this setting, an incidence or causal relationship cannot be accurately determined. CAPTOPRIL: adverse_reactions: Body as a Whole : Anaphylactoid reactions [0m[1;31m([0m[31msee [0m
[31mWARNINGS: Captopril: Anaphylactoid and Possibly Related Reactions and PRECAUTIONS: Hemodialysis [0m[1;31m)[0m[31m. General : asthenia, gynecomastia. Cardiovascular : cardiac arrest, cerebrovascular [0m
[31maccident/insufficiency, rhythm disturbances, orthostatic hypotension, syncope. Dermatologic : bullous pemphigus, erythema multiforme [0m[1;31m([0m[31mincluding Stevens-Johnson syndrome[0m[1;31m)[0m[31m, exfoliative dermatitis. [0m
[31mGastrointestinal : pancreatitis, glossitis, dyspepsia. Hematologic : anemia, including aplastic and hemolytic. Hepatobiliary : jaundice, hepatitis, including rare cases of necrosis, cholestasis. [0m
[31mMetabolic : symptomatic hyponatremia. Musculoskeletal : myalgia, myasthenia. CAPTOPRIL: adverse_reactions: Nervous/Psychiatric : ataxia, confusion, depression, nervousness, somnolence. Respiratory : [0m
[31mbronchospasm, eosinophilic pneumonitis, rhinitis. Special Senses : blurred vision. Urogenital : impotence. As with other ACE inhibitors, a syndrome has been reported which may include: fever, myalgia,[0m
[31marthralgia, interstitial nephritis, vasculitis, rash or other dermatologic manifestations, eosinophilia and an elevated ESR. Fetal/Neonatal Morbidity and Mortality: See WARNINGS: Captopril: [0m
[31mFetal/Neonatal Morbidity and Mortality . Hydrochlorothiazide : Gastrointestinal System : anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice [0m[1;31m([0m[31mintrahepatic [0m
[31mcholestatic jaundice[0m[1;31m)[0m[31m, pancreatitis, and sialadenitis. CAPTOPRIL: adverse_reactions: Central Nervous System : dizziness, vertigo, paresthesias, headache, and xanthopsia. Hematologic : leukopenia, [0m
[31magranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia. Cardiovascular : orthostatic hypotension. Hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotizing angiitis [0m
[1;31m([0m[31mvasculitis; cutaneous vasculitis[0m[1;31m)[0m[31m, fever, respiratory distress including pneumonitis, and anaphylactic reactions. Other : hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, [0m
[31mrestlessness, and transient blurred vision. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn. CAPTOPRIL: adverse_reactions: Altered Laboratory [0m
[31mFindings: Serum Electrolytes : Hyperkalemia: small increases in serum potassium, especially in patients with renal impairment [0m[1;31m([0m[31msee PRECAUTIONS: Captopril [0m[1;31m)[0m[31m. Hyponatremia : particularly in patients [0m
[31mreceiving a low sodium diet or concomitant diuretics. BUN/Serum Creatinine : Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with renovascular [0m
[31mhypertension may occur. Rapid reduction of longstanding or markedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum [0m
[31mcreatinine. Hematologic : A positive ANA has been reported. Liver Function Tests : Elevations of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred. CAPTOPRIL: [0m
[31madverse_reactions: Postmarketing Experience : Non-melanoma Skin Cancer : Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel [0m
[31mSystem, increased risk was predominantly for squamous cell carcinoma [0m[1;31m([0m[31mSCC[0m[1;31m)[0m[31m and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately [0m[1;31m1[0m
[31madditional case per [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients per year, and for white patients taking a cumulative dose of â‰¥ [0m[1;31m50[0m[31m,[0m[1;31m000[0m[31m mg the risk increase was approximately [0m[1;31m1[0m[31m additional SCC case for every [0m[1;31m6[0m[31m,[0m[1;31m700[0m[31m patients per [0m
[31myear. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m- [0m[1;31m874[0m[31m-[0m[1;31m7464[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Rarely, ACE inhibitors, which include CAPTOPRIL, have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and [0m[1;32m([0m[32msometimes[0m[1;32m)[0m[32m death. [0m
[32mThe mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive [0m
[32mappropriate medical follow-up.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: Hepatic Failure : Rarely, ACE[0m[32m...[0m[32mappropriate medical follow-up.[0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Rarely, ACE inhibitors, which include CAPTOPRIL, have been [0m
[34massociated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and [0m[1;34m([0m[34msometimes[0m[1;34m)[0m[34m death. The mechanism of this syndrome is not understood. Patients [0m
[34mreceiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: Hepatic Failure : Rarely, ACE[0m[34m...[0m[34mappropriate medical follow-up.[0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CAPTOPRIL increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that ACE inhibitors, which include CAPTOPRIL, have been rarely associated with a syndrome that starts with cholestatic jaundice and can progress to fulminant hepatic [0m
[32mnecrosis and sometimes death. The mechanism of this syndrome is not understood, and patients who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and [0m
[32mreceive appropriate medical follow-up."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CAPTOPRIL, as an ACE inhibitor, can rarely increase the risk of a syndrome that may lead to acute liver injury, starting with cholestatic jaundice and potentially progressing to [0m
[32mfulminant hepatic necrosis and sometimes death."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CAPTOPRIL increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that ACE inhibitors, which include CAPTOPRIL, have been rarely associated with a syndrome that starts with cholestatic jaundice and can progress to fulminant hepatic [0m
[34mnecrosis and sometimes death. The mechanism of this syndrome is not understood, and patients who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and [0m
[34mreceive appropriate medical follow-up."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CAPTOPRIL, as an ACE inhibitor, can rarely increase the risk of a syndrome that may lead to acute liver injury, starting with cholestatic jaundice and potentially progressing to [0m
[34mfulminant hepatic necrosis and sometimes death."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CAPTOPRIL increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that ACE inhibitors, which include CAPTOPRIL, have been rarely associated with a syndrome that starts with cholestatic jaundice and can progress to fulminant hepatic necrosis [0m
[31mand sometimes death. The mechanism of this syndrome is not understood, and patients who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive [0m
[31mappropriate medical follow-up.[0m
[31m        -----[0m
[31m        Final answer: CAPTOPRIL, as an ACE inhibitor, can rarely increase the risk of a syndrome that may lead to acute liver injury, starting with cholestatic jaundice and potentially progressing to [0m
[31mfulminant hepatic necrosis and sometimes death.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mCAPTOPRIL, as an ACE inhibitor, can rarely increase the risk of a syndrome that may lead to acute liver injury, starting with cholestatic jaundice and potentially progressing to fulminant hepatic [0m
[32mnecrosis and sometimes death. This information is based on the CAPTOPRIL label provided by the FDA, which states that this association is rare and the mechanism of the syndrome is not understood. [0m
[32mPatients who develop jaundice or marked elevations of hepatic enzymes while on CAPTOPRIL should discontinue the medication and receive appropriate medical follow-up.[0m
